Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis

Radboud University Nijmegen Medical Centre, Department of General Practice, Nijmegen, The Netherlands.
Respiratory medicine (Impact Factor: 3.09). 02/2009; 103(4):542-51. DOI: 10.1016/j.rmed.2008.11.003
Source: PubMed


Increased oxidative stress and bronchial inflammation are important mechanisms in the pathophysiology of COPD.
To investigate whether treatment with the inhaled corticosteroid fluticasone propionate (FP) or the anti-oxidative agent N-acetylcysteine (NAC) are effective in primary care patients.
The study was a 3-year placebo-controlled randomised controlled trial preceded by a 3-month washout and 2-week prednisolone pre-treatment. Patients were (ex-)smokers with chronic bronchitis or COPD. Interventions were inhaled FP 500microg b.i.d., oral NAC 600mg o.d., or placebo. Exacerbation rate and quality of life measured with the Chronic Respiratory Questionnaire (CRQ) were the primary outcomes, FEV(1) decline and respiratory symptoms secondary outcomes.
286 patients recruited from 44 general practices were randomised. Exacerbation rate was 1.35 times higher for NAC (p=0.054) and 1.30 times higher for FP (p=0.095) compared with placebo. CRQ total scores did not differ between NAC (p=0.306) or FP (p=0.581) treatment compared to placebo. Annual postbronchodilator FEV(1) decline was 64mL [SD 5.4] for NAC [p=0.569 versus placebo], 59mL [SD 5.7] for FP [p=0.935], and 60mL [SD 5.4] for placebo.
No beneficial treatment effects for either high-dosed inhaled fluticasone propionate or oral N-acetylcysteine were observed in our study population of patients with COPD or chronic bronchitis.

Download full-text


Available from: Niels Chavannes
  • [Show abstract] [Hide abstract]
    ABSTRACT: The 2009 American Thoracic Society (ATS) International Conference was held in sunny San Diego, California, from 15 to 20 May. This review aims to summarise some of the key sessions relating to COPD, providing an update on developments over the past 12 months. The two keynote lectures 'Clinical Year in Review' on COPD and Pulmonary Rehabilitation were delivered by Dr Mark Eisner from the University of California, San Francisco and Dr Denis O'Donnell, Queens University, Kingston, Canada respectively. Several topics related to COPD were discussed at these sessions, including:•Risk factors for COPD-beyond personal smoking•Clinical Trials: COPD Progression and Long-tem Outcomes•Mucolytic therapy•Pulmonary Rehabilitation. In the sections below we will expand on these themes and discuss some of the other areas relating to COPD at this year's conference.
    No preview · Article · Aug 2009 · Respiratory Medicine COPD Update
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The oral prednisolone test is widely used to distinguish chronic obstructive pulmonary disease (COPD) patients who might benefit from inhaled steroid treatment. Previous studies used selected patient groups that did not represent the large COPD population in primary care. The study included smokers and exsmokers with chronic bronchitis or COPD from primary care, who underwent prednisolone testing (30 mg for 14 days) before randomization in a three-year follow-up randomized controlled trial (COOPT Study). Spirometry was performed before and after the test. Responders and nonresponders were classified according to international criteria. Effectiveness of inhaled fluticasone relative to placebo was compared in terms of health status (Chronic Respiratory Disease Questionnaire), exacerbations, and postbronchodilator forced expiratory volume in one second (FEV(1)), using repeated measurement analysis. Two hundred eighty-six patients recruited from 44 primary care practices were randomized. Nine percent to 16% of the COPD population was classified as responder, depending on the international guideline criteria used. On average, responders did not reach the minimum clinically important difference in health status (0.29 points/year, P = 0.05), although a borderline significant effect of inhaled fluticasone was noted. Possible clinically relevant reductions in exacerbation rate (rate ratio 0.67) and FEV(1) decline (39 mL/year) occurred in responders, but did not reach statistical significance. Oral steroid testing identifies a limited proportion of COPD patients, but does not reveal any clinically relevant benefit from inhaled steroid treatment on health status. No significant effects on exacerbation rate and lung function decline occurred.
    Full-text · Article · Nov 2009 · International Journal of COPD
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Samenvatting Chavannes NH, Schermer TRJ, Wouters EFM, Akkermans RP, Dekhuijzen PNR, Muris JWM, et al. Het nut van de orale prednisontest bij de behandeling van COPD in de eerste lijn. Huisarts Wet 2010;5:272-6.
    Full-text · Article · May 2010 · Huisarts en wetenschap
Show more